At present there are no standard therapies for the adjuvant treatment of malignant melanoma. Patients with primary tumours with a high Breslow thickness (stages IIB and IIc) or with resected loco-regional nodal disease (stage III) are at a high-risk of developing metastasis and subsequent disease-related death. Given this, it is important that novel therapies are investigated in the adjuvant melanoma setting. Since angiogenesis is essential for primary tumour growth and the development of metastasis, anti-angiogenic agents are attractive potential therapeutic candidates for clinical trials in the adjuvant setting. Therefore, we initiated a Phase II trial in resected high-risk cutaneous melanoma assessing the efficacy of bevacizumab versus observation.
In the interim safety data analysis, we demonstrate that bevacizumab is a safe therapy in the adjuvant melanoma setting with no apparent increase in the surgical complication rate after either primary tumour resection and/or loco-regional lymphadenectomy.
Further information:
Related posts:
- Impact of a reduced dose intensity of adjuvant anthracycline based chemotherapy in a population-based cohort of stage I-II breast cancers
- Mitf-Mdel, a novel melanocyte/melanoma-specific isoform of microphthalmia-associated transcription factor-M, as a candidate biomarker for melanoma
- Increased shedding of HU177 correlates with worse prognosis in primary melanoma
- A tailored lifestyle intervention to reduce the cardiovascular disease risk of individuals with Familial Hypercholesterolemia (FH): design of the PRO-FIT randomised controlled trial.
- A Randomised Prospective Study of Extended Tocopherol and Pentoxifylline Therapy, in Addition to Carbogen, in the Treatment of Radiation Late Effects
Posted in